A patient suffering from diabetic foot ulcers losses the ability to feel pain. Redness and swelling of the foot are some common symptoms of the disease. Several topical therapeutics are available for the treatment of diabetic foot ulcers such as polyhexamethylene biguanide gel or solutions, dressings containing silver or silver sulphadiazine cream, iodine, and medical grade honey in ointment or gel form.
The global diabetic foot ulcer therapeutics market is estimated to account for US$ 4,901.1 Mn in terms of value in 2018 and is estimated to reach US$ 12,021.8 Mn by the end of 2027.
Global Diabetic Foot Ulcer Therapeutics Market: Drivers
Developments in regenerative technology are expected to boost growth of the global diabetic foot ulcer therapeutics market over the forecast period. For instance, in July 2019, AVITA Medical announced positive results for a study that assessed its RECELL Autologous Cell Harvesting Device for the treatment of diabetic foot ulcers.
Global Diabetic Foot Ulcer Therapeutics Market: Opportunities
Increasing incidence of obesity is expected to offer lucrative growth opportunities for players in the market. For instance, according to MedAlertHelp.org, over 1.9 billion adults were reported as overweight worldwide.
Global Diabetic Foot Ulcer Therapeutics Market: Restraints
Availability of alternatives such as diabetic shoes and natural remedies are expected to hamper growth of the global diabetic foot ulcer therapeutics market.
Advanced wound dressings segment in the global diabetic foot ulcer therapeutics market was valued at US$ 1,935.6 Mn in 2018 and is expected to reach US$ 3,583.0 Mn by 2027 at a CAGR of 7.3% during the forecast period. Increasing product launches is expected to support growth of the segment over the forecast period. For instance, KCI, an Acelity Company recently expanded its advanced wound dressings (AWD) presence in South Africa with the launch of Kerracontact Ag Dressing, Kerrafoam Gentle Border Dressing and Kerramax Care Dressing in July 2019.
The Neuropathic Ulcers segment held dominant position in the global diabetic foot ulcer therapeutics market in 2018, accounting for 50.5% share in terms of value, followed by Neuro-Ischemic Ulcers and Ischemic Ulcers, respectively. Rising prevalence of diabetes is a major factor driving growth of the segment. As According to WHO, The number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. According to a report published by Center for Disease Control and Prevention in 2017, over 100 million of the adults in the U.S. are suffering from prediabetes or diabetes
The hospitals segment held dominant position in the global diabetic foot ulcer therapeutics market in 2018, accounting for 37.2% share in terms of value, followed by Specialty Clinics and Long Term Care Centers, respectively. Increasing hospitalizations for treatment of diabetes foot ulcers is expected to support growth of the segment. For instance, according to diabetes Australia, every year there are 10,000 hospital admissions in Australia for diabetes-related foot ulcers
The market in emerging economies is driven by rapid growth in medical tourism. For instance, according to India Brand Equity Foundation’s January 2019 release, the estimated Foreign Tourist Arrivals (FTAs) in India on medical purpose during the years 2015, 2016, and 2017 were 2,33,918, 4,27,014, and 4,95,056 respectively.
Epidermal growth factor is effective in the treatment of diabetic foot ulcers. For instance, in July 2019, researchers at University of Debrecen (Hungary) and Thach University of Medicine (Vietnam) reported positive results for the use of recombinant human epidermal growth factor in the treatment of diabetic foot ulcers.
Global Diabetic Foot Ulcer Therapeutics Market: Competitive Landscape
Major players operating in the global diabetic foot ulcer therapeutics market include, B. Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc., Derma Sciences Inc., Sigvaris Inc., 3M, and Acelity L.P. Inc.
Global Diabetic Foot Ulcer Therapeutics Market: Key Developments
December 2019: Orpyx Medical Technologies Inc. launched Orpyx SI Sensory Insoles with Remote Patient Monitoring for the prevention of diabetic foot ulcers and neuropathy-related ulcers
November 2019: Pergamum AB, a subsidiary of Promore Pharma AB, a Sweden –based biopharmaceutical company, received a patent in the US for the pharmaceutical formulation of the product candidate PXL01 used for the treatment of diabetic foot ulcers